- Home
- Automated
- List of product information
- XALACOM EYE DROPS [SIN11922P]
XALACOM EYE DROPS [SIN11922P]
Active ingredients: XALACOM EYE DROPS
Last updated 26 October 2025
On this page
Product Info
XALACOM EYE DROPS
[SIN11922P]
Product information
Active Ingredient and Strength | LATANOPROST - 50 MCG/ML |
Dosage Form | SOLUTION |
Manufacturer and Country | PFIZER MANUFACTURING BELGIUM N.V. - BELGIUM |
Registration Number | SIN11922P |
Licence Holder | VIATRIS PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01ED51 |
4.1. Therapeutic Indications
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to another topical IOP lowering agent.
4.2. Posology and Method of Administration
Use in adults (including the elderly):
One drop in the affected eye(s) once daily.
The use of Xalacom may be considered in patients who require both timolol and latanoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus latanoprost given once daily will be as well controlled with Xalacom given once daily. Xalacom should be used for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to another intraocular lowering pressure medication.
Xalacom should not be used more than once daily because latanoprost is most effective when given once daily. If there is an insufficient response to Xalacom, then consideration should be given to using the individual agents with timolol dosed twice daily.
If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
If more than one topical ophthalmic drug is being used, they should be administered at least five minutes apart.
Contact lenses should be removed before instillation of the eye drops and may be reinserted after fifteen minutes (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.
Use in children:
Safety and effectiveness in children and adolescents have not been established.
4.3. Contraindications
Latanoprost-timolol maleate is contraindicated in patients with:
Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, or cardiogenic shock.
Known hypersensitivity to latanoprost, timolol maleate, or any other component of the product.